Neurobiology of Aging
Volume 30, Issue 5 , Pages 682-690 , May 2009

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment

  • Miroslaw Brys

      Affiliations

    • New York University School of Medicine, NY, USA
    • ,
  • Elizabeth Pirraglia

      Affiliations

    • New York University School of Medicine, NY, USA
    • ,
  • Kenneth Rich

      Affiliations

    • New York University School of Medicine, NY, USA
    • ,
  • Sindre Rolstad

      Affiliations

    • University of Goeteborg, Sweden
    • ,
  • Lisa Mosconi

      Affiliations

    • New York University School of Medicine, NY, USA
    • ,
  • Remigiusz Switalski

      Affiliations

    • New York University School of Medicine, NY, USA
    • ,
  • Lidia Glodzik-Sobanska

      Affiliations

    • New York University School of Medicine, NY, USA
    • ,
  • Susan De Santi

      Affiliations

    • New York University School of Medicine, NY, USA
    • ,
  • Ray Zinkowski

      Affiliations

    • Applied Neurosolutions, Vernon Hills, IL, USA
    • ,
  • Pankaj Mehta

      Affiliations

    • Institute for Basic Research, Staten Island, NY, USA
    • ,
  • Domenico Pratico

      Affiliations

    • University of Pennsylvania, Philadelphia, PA, USA
    • ,
  • Leslie A. Saint Louis

      Affiliations

    • New York University School of Medicine, NY, USA
    • ,
  • Anders Wallin

      Affiliations

    • University of Goeteborg, Sweden
    • ,
  • Kaj Blennow

      Affiliations

    • University of Goeteborg, Sweden
    • ,
  • Mony J. de Leon

      Affiliations

    • New York University School of Medicine, NY, USA
    • Nathan Kline Institute, Orangeburg, NY, USA
    • Corresponding Author InformationCorresponding author at: Center for Brain Health, 550 First Avenue MHL-400, New York, NY 10016, USA. Tel.: +1 212 263 5805; fax: +1 212 263 3270.

Received 21 March 2007 ,Revised 13 July 2007 ,Accepted 15 August 2007.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. fourth ed.. Washington, DC: American Psychiatric Association; 1994;
  2. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. 1999;273(1):5–8
  3. Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp. Neurol. 2000;166(1):201–203
  4. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837–1844
  5. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2(10):605–613
  6. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol. Chem. Neuropathol. 1995;26(3):231–245
  7. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368(9533):387–403
  8. Brys M, Mosconi L, De Santi S, Rich KE, de Leon MJ. CSF Biomarkers for mild cognitive impairment. Aging Health. 2006;2(1):111–121
  9. Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59(4):627–629
  10. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 2002;59(8):1267–1272
  11. Consensus Working Group. 1998. Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer's disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging. Neurobiology of Aging 19, 109–116.
  12. de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci. Lett. 2002;333(3):183–186
  13. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging. 2006;27(3):394–401
  14. de Leon, M.J., Mosconi, L., Li, J., De Santi, S., Yao, Tsui, W.H., Pirraglia, E., Rich, K., Javier, E., Brys, M., Sobanska, L., Switalski, R., Saint Louis, L.A., Pratico, D., in press. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J. Neurol.
  15. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De LE, et al. No association of CSF biomarkers with APOE4, plaque and tangle burden in definite Alzheimer's disease. Brain. 2007;
  16. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid42 ratio as a prediction of cognitive decline in non-demented older adults. Arch. Neurol. 2007;
  17. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 1998;55(7):937–945
  18. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma abeta42/abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 2007;64(3):354–362
  19. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–234
  20. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2007;23(5):316–320
  21. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. 2001;15(4):169–173
  22. Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttila T. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol. Aging. 2007;28(4):507–514
  23. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology. 1999;52(8):1555–1562
  24. Hyman BT, Van Hoesen GW, Wolozin BL, Davies P, Kromer LJ, Damasio AR. Alz-50 antibody recognizes Alzheimer-related neuronal changes. Ann. Neurol. 1988;23(4):371–379
  25. Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 2000;287(3):187–190
  26. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF A[beta]42, A[beta]42/A[beta]40 ratio and total tau. Neurobiol. Aging. 2004;25(3):273–281
  27. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N. Engl. J. Med. 1998;338:506–511
  28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944
  29. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch. Neurol. 2000;57(1):100–105
  30. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 1998;44(3):410–413
  31. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 1995;38(4):643–648
  32. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999;56(3):303–308
  33. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch. Neurol. 2001;58(12):1985–1992
  34. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 2000;48(5):809–812
  35. Pratico D, Rokach J, Lawson J, FitzGerald GA. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem. Phys. Lipids. 2004;128(1–2):165–171
  36. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann. Neurol. 1999;45(3):358–368
  37. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.. Neurology. 2004;62(11):2116–2118
  38. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am. J. Psychiatry. 1982;139(9):1136–1139
  39. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble beta 1–40 is linked to cerebral amyloid angiopathy. Am. J. Pathol. 1994;145(2):452–460

PII: S0197-4580(07)00345-4

doi: 10.1016/j.neurobiolaging.2007.08.010

Neurobiology of Aging
Volume 30, Issue 5 , Pages 682-690 , May 2009

Article Tools

* Image Usage & Resolution